Millions could be vaccinated against Covid-19 as UK secures strong portfolio of promising vaccines

The UK has secured early access to 90 million vaccine doses from the BioNTech/Pfizer alliance and Valneva as part of its vaccination strategy. It has also secured treatments containing Covid-19-neutralising antibodies from AstraZeneca to protect those who cannot receive vaccines.

SPS commentary:

Other developments include the following:

The Government has launched the NHS Covid-19 vaccine research registry. This new online service will allow members of the public to register their interest and be contacted to participate in clinical studies. To enable large-scale vaccine studies to take place across the UK, the aim is to get 500,000 people signed up by October.

The Government is working with ZOE, the health science company using data driven research from the symptom study app and site, to look at collaborating around vaccine studies and to help their volunteers hear about how to sign up to the NHS registry.

The three different vaccine classes that the Government has secured to date for the UK are adenoviral vaccines (Oxford/AstraZeneca), mRNA vaccines (BioNTech/Pfizer, Imperial) and inactivated whole virus vaccines (Valneva).


Department of Health and Social Care